2021-03-31-accounts

Charity Registration No. 1082702

UK MYELOMA FORUM

ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2021

UK MYELOMA FORUM

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Prof G Cook
	Dr J Ashcroft
	Dr N Rabin
	Dr G Pratt
	Dr M Kaiser
	Dr K Ramasamy
	Dr S Stern
	Dr R Popat
	Dr M Jenner
	S Henshaw
	Dr S Lawless
	Dr R Soutar
	Dr R Hall
	Dr J Sive
	Dr S Lawson
	Dr M Streetly
	Dr C Bygrave
	L Kerby
Charity number	1082702
Principal address	Royal Bournemouth Hospital
	Castle Lane East
	Bournemouth
	BH7 7DW
Independent examiner	Joel Courts
	c/o HW Fisher LLP
	Chartered Accountants
	Acre House
	11-15 William Road
	London
	NW1 3ER
Bankers	Adam & Co
	25 St Andrew Square
	Edinburgh
	EH2 1AF

UK MYELOMA FORUM

CONTENTS

	Page
Trustees' report	1 - 7
Independent examiner's report	8
Statement of financial activities	9
Balance sheet	10
Notes to the accounts	11 - 17

Trustees' Annual Report for the period

Period start date Period end date

Day Month Year Day Month Year From 1 April 2020 To 31 March 2021

Section A Reference and administration details

Charity name

UK Myeloma Forum

Other names charity is known by

UKMF

Registered charity number (if any) 1082702

Charity's principal address Royal Bournemouth Hospital

Castle Lane East Bournemouth Postcode BH7 7DW

Names of the charity trustees who manage the charity

----- Start of picture text -----
Name of person
(or body) entitled
Trustee name Office (if any) Dates acted if not for whole year
to appoint
trustee (if any)
Dr John Ashcroft Chair / Board member Chair November 2015 -
1.
November 2021
(Leeds, Mid Yorks)
Board November 2019 -November
2. [Dr Rachel Hall ]
Member/Treasuer 2023
(Bournemouth)
Past Chair/HTA lead November 2019- November
3. [Prof Gordon Cook ]
2021
(Leeds)
Chair Elect January 2013 - November 2021
4. [Dr Neil Rabin ]
(London)
Dr Guy Pratt Secretary November 2013-November
5.
2023
(Birmingham)
Dr Martin Kaiser Board member January 2018 – January 2022
6.
(London)
Communications Lead November 2014 - June 2022
7. [Dr Karthik Ramasamy ]
(Oxford)
Guidelines Secretary June 2017 - June 2023
8. [Dr Simon Stern ]
(Surrey)
Dr Matthew Streetly Advocacy lead January 2014 - January 2020
9.
(London)
Science Lead November 2018 - November
10. [Dr Rakesh Popat ]
2021
(London)
Board member March 2018 - March 2022
11. [Dr Matthew Jenner ]
(Southampton)
----- End of picture text -----

2020-2021

TAR 1

----- Start of picture text -----
Dr Jonathan Sive Board member January 2020 -January 2023
12.
(London)
Sarah Henshaw Myeloma Nurse Lead November 2018 -November
13.
2021
(Nottingham)
Dr Ceri Bygrave Wales Representative November 2015 -November
14.
(Cardiff) (Invited Board member) 2021
Dr Sarah Lawless N.Ireland January 2018 -January 2024
15. Representative
(N.Ireland)
(Invited Board member)
Scotland Representative December 2017 -January 2024
16. [Dr Richard Soutar ]
(Glasgow) (Invited Board member)
Board member January 2020 – January 2023
17. [Dr Michelle Lawson ]
(Sheffield)
----- End of picture text -----

Names of the trustees for the charity, if any, (for example, any custodian trustees)

Name Dates acted if not for whole year

Names and addresses of advisers (Optional information)

Type of adviser	Name	Address
Independent Examiner	Joel Courts, HW Fisher LLP	Acre House 11-15 William Road London NW1 3ER
Bankers	Adam & Co	25 St Andrew Square, Edinburgh, EH2 1AF

Name of chief executive or names of senior staff members (Optional information)

Section B Structure, governance and management

Description of the charity’s trusts

Type of governing document (eg. trust deed, constitution)[Constitution ] How the charity is constituted (eg. trust, association, company)[Association ] Trustee selection methods Elected from membership (eg. appointed by, elected by)

2020-2021

TAR

2

Additional governance issues (Optional information)

You may choose to include additional information, where relevant, about:

• policies and procedures adopted for the induction and training of trustees;

• the charity’s organisational structure and any wider network with which the charity works;

• relationship with any related parties;

• trustees’ consideration of major risks and the system and procedures to manage them.

Section C Objectives and activities

The Charity’s objects (“the objects”) are

Summary of the objects of the charity set out in its governing document

1. The advancement of education of the general public, in particular in the treatment of those suffering from myeloma and related disorders, through the promotion and conduct of research and the publication and dissemination of all useful results of such research.

2. The relief of persons suffering from myeloma and related disorders, in particular by

3. a) the development and provision of policy guidelines for their treatment b) promoting an understanding of the issues relating to myeloma and related disorders by encouraging communication and the exchange of information between research groups and healthcare professionals.

Summary of the main The UKMF had a further active year in pursuit of its’ charitable objectives which activities undertaken for the are, education, research and advocacy. public benefit in relation to To that end three Executive Committee meetings were held in 2020-2021; June these objects (include within 2020, November 2020 and March 2021. this section the statutory declaration that trustees have In keeping with our objectives we have made significant progress in a number of key had regard to the guidance areas including educational meetings, guidelines and advocacy. These are issued by the Charity summarised in the following pages. Commission on public benefit)

2020-2021

TAR

3

Additional details of objectives and activities (Optional information)

Revenue for corporate sponsorship contributed £133,560 ( April 2020-March 2021). This re-enforces the support by pharma for the work that the UKMF undertakes. Due to Covid-19, the Autumn Day became an entirely virtual meeting and was held on 11th November 2020. The programme theme was ‘Accelerating Research: Better Trial Designs, Better Therapies’ and featured Professor Mohamad Mohty from Saint You may choose to include Antoine Research Centre, Paris. Prof. Mohty presented the Michael Morley Lecture further statements, where on ‘A journey from past to future’. relevant, about: The Spring Day was also a virtual meeting and was held on 17[th] March 2021. The  policy on grantmaking; theme for this meeting was the, ‘Impact of Covid on Multiple Myeloma Management’. The plenary lecture was given by Dr Maheshi Ramasamy from the  policy programme related University of Oxford. Her talk was entitled, ‘The Oxford Astra Zeneca vaccineinvestment; developing a global vaccine against COVID-19.  contribution made by A number of travel grants for scientific conferences were awarded in 2020 to volunteers. winning abstracts. Three bursaries of £350 covered the registration fee for ASH (American Society of Haematology Annual Meeting). This meeting was virtual due to Covid-19 travel restrictions. The ASH abstracts were presented at the Spring Day in March 2021. A review of ASH was produced in the e-newsletter. Initially, two travel grants of £700 were awarded to attend the EMN meeting (European Myeloma Network) from 16[th] -18[th] April 2020 in Amsterdam. However, this meeting was cancelled and later postponed to March 2021 due to the global pendemic. The bursary funds have been returned to the UKMF.

Section D Achievements and performance	Section D Achievements and performance
Summary of the main achievements of the charity during the year
	The annual meetings Producing two successful and well attended educational meetings on a new virtual platform in November 2020 and March 2021. For details, please refer to the section above and the UKMF website for programme and talks from these meetings. Please refer to the UKMF website for the programme and talks from the education meeting. Travel grants for scientific meetings The UKMF in collaboration with the Michael Morley Fund awarded a number of bursaries in 2020-21 to support the attendance of young investigators and specialist nurses at ASH Virtual (American Society of Haematology Meeting) in December 2020. Recipients of the bursaries presented their data at the UKMF Spring Day in March 2021. This is a regular and successful session. For the ASH bursary winners, recipients prepared a short review for the UKMF website and were credited in the UKMF e-newsletter. Advocacy The UKMF members have continued to engage with the NICE technology appraisals both in newly diagnosed and relapsed myeloma. Members of the UKMF also help develop NICE clinical guidelines and more recently input into NHS England Algorithm. The Guidelines group The UKMF Guidelines Group remained active despite the difficulties caused by the Covid-19 pandemic, good progress had been made on the development of 2 new separate sets of guidelines on the management of both newly diagnosed and relapsed multiple myeloma.

2020-2021

TAR

4

Section D Achievements and performance

A full first draft of the newly diagnosed guidelines had been reviewed by the BSH Haemato-oncology Task Force and BSH Guidelines Committee. A first full draft of the relapsed guidelines was near completion.

In addition, writing groups had been set up with a view to producing Good Practice Papers (GPPs) on the diagnosis and management of both MGUS and MGRS.

Myeloma Nurse Group

Due to COVID, the Nurse group understandably had not been as active in 2020. However, the group planned to pull together details on the impact of COVID to Myeloma Nursing Care in preparation for the Spring Day 2021. The nurse group also planned to do a best practice guide for Peripheral Neuropathy. College of Myeloma (UK) Created in 2019, the College of Myeloma (UK) consists of elected fellows representing those who have contributed significantly to the work of the UKMF and to patients with Myeloma through medical science, education and clinical care.

• Fellows will be nominated and elected to the College.

• Elected fellows will be known as Fellows of the College of Myeloma (UK) and can use the designation of F.C.My.(UK), should they wish.

• The College will be led by a Dean (Professor Gordon Cook), elected from the College fellowship on a 3 yearly basis.

• The aim is to elect one fellow per year. • two fellows will be elected each year for the first 5 years

  • then one per year afterwards.

  • Until the College has a core of fellows, the UKMF Executive committee shall vote on the nominees for each year.

• The election process will be coordinated by the sitting past-Chair of the UKMF, both in the first five years of establishing the College, and thereafter thus ensuring the continually engagement and involvement by the UKMF in the establishment of the College

The Fellows of the College will provide guidance to the Society in order for the Society to deliver on its organisational strategy. Consequently, Fellows of the College will serve to:

• Individually, provide expert input to the delivery of medical education, either through advice on content or the provision of content in line with the UKMF Education strategy.

• Individually, provide mentorship for developing professionals in the field of plasma cell disorders, to assist in career development.

• Individually, where appropriate, assist in the governance of the clinical research program as directed by the Society’s research strategy delivered through the UK Myeloma Research Alliance

• Collectively provide advice and guidance on patient advocacy in accordance with the Society’s advocacy strategy.

• Collectively provide support and guidance on matters of public policy, health technology appraisals and national service delivery strategies as affect patients with myeloma.

2019 fellows : Professor Curly Morris Professor Kwee Yong 2020 fellows : Professor Keith Stewart Professor Steve Schey 2021 fellows: Professor Graham Jackson Dr Jenny Bird Professor Mark Cook

2020-2021

TAR

5

Section E Financial review

The UKMF’s policy on reserves is to maintain sufficient level of funds to enable Brief statement of the charity’s operating activities to be supported, taking account of potential risks and policy on reserves contingencies that may arise from time to time. The policy is reviewed annually by the Trustees.

Details of any funds materially in deficit

Not applicable

Further financial review details (Optional information)

Income You may choose to include Education Grants from Corporate Sponsors contributed £133,560 in the year 2020additional information, where 2021. £68,261 was received in 2019-2020. relevant about:  the charity’s principal Micheal Morley fund at the end of the 2020-2021 tax year stood at £277,212 compared to £233,148 in the previous year. sources of funds (including any fundraising); Total income from the 2020-2021 year was £137,923 (2020: £73,859).  how expenditure has supported the key objectives The Michael Morley Fund This fund is a charitable donation from a patient’s estate that is invested on behalf of of the charity; the UKMF and the interest may be used towards certain projects including  investment policy and supporting two Michael Morley lectures per annum. See section D for further objectives including any details). ethical investment policy Expenditure adopted. Administrative costs (covering Executive meetings and associated expenses and the salary and on-costs of our Administrative Secretary, accountants’ fees, employer’s liability insurance and teleconferencing) at £34,412 (2020: £34,291). Spring and Autumn educational meetings in the 20-21 year at £17,217 (2020: £44,730).

Travel bursaries to ASH 2020 amounting to £1,050 (2020: £6,000).

Reserves The UKMF’s unrestricted reserves remain sound as of 31st March 2021 and were approximately £137,617 (2020: £57,357).

Section F Other optional information

Section G Declaration

The trustees declare that they have approved the trustees’ report above.

Signed on behalf of the charity’s trustees

2020-2021

TAR

6

Signature(s) Full name(s) Dr Rachel Hall Position (eg Secretary, Chair, Treasurer etc) Date 28 Jan 2022

2020-2021

TAR

7

UK MYELOMA FORUM

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF UK MYELOMA FORUM

I report to the trustees on my examination of the financial statements of UK Myeloma Forum (the charity) for the year ended 31 March 2021.

Responsibilities and basis of report

As the trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity’s financial statements carried out under section 145 of the 2011 Act . In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

• 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or

• 2 the financial statements do not accord with those records; or

• 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Joel Courts

Joel Courts c/o HW Fisher LLP Chartered Accountants Acre House 11-15 William Road London NW1 3ER

28 Jan 2022

Dated: .........................

• 8 -

UK MYELOMA FORUM

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 MARCH 2021

Unrestricted Unrestricted funds funds general d esignated 2021 2021 Notes £ £ Income from: Donations and legacies 3 133,560 - Investments 4 29 4,334 Total income 133,589 4,334 Expenditure on: Raising funds 5 - 1,436 Charitable activities 6 53,329 - Total resources expended 53,329 1,436 Net gains/(losses) on investments 11 - 41,166 Net movement in funds 80,260 44,064 Fund balances at 1 April 2020 57,357 233,148 Fund balances at 31 March 2021 137,617 277,212	Total Unrestricted Unrestricted funds funds general d esignated 2021 2020 2020 £ £ £ 133,560 68,261 - 4,363 301 5,297 137,923 68,562 5,297 1,436 - 1,542 53,329 85,896 - 54,765 85,896 1,542 41,166 - (27,595) 124,324 (17,334) (23,840) 290,505 74,691 256,988 414,829 57,357 233,148	Total 2020 £ 68,261 5,598 73,859 1,542 85,896 87,438 (27,595) (41,174) 331,679 290,505

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

• 9 -

UK MYELOMA FORUM

BALANCE SHEET

AS AT 31 MARCH 2021

Notes Fixed assets Investments 12 Current assets Debtors 13 Cash at bank and in hand Creditors: amounts falling due within one year 14 Net current assets Total assets less current liabilities Income funds Unrestricted funds - designated 15 Unrestricted funds - general 28 Jan 2022	2021 £ 283 202,392 202,675 (6,058)	£ 218,212 196,617 414,829 277,212 137,617 414,829	2020 £ 1,430 162,266 163,696 (47,339)	£ 174,148 116,357
				290,505
				233,148 57,357
				290,505

The financial statements were approved by the Trustees on .........................

.............................. Dr Rachel Hall

Trustee

• 10 -

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2021

1 Accounting policies

Charity information

UK Myeloma Forum is a charity registered in England and Wales and is governed by its constitution. The Charity meets the defination of a public benefit entity under FRS 102. The registered office is Department of Haematology, Royal Bournemouth Hospital, Bournemouth, Dorset, BH14 9QN

1.1 Accounting convention

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and “Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)” (effective from 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements are prepared in sterling , which is the functional currency of the charity . Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

1.2 Going concern

The trustees have considered the effect of the prolonged Covid-19 outbreak. The trustees consider that the outbreak is unlikely to cause significant disruption to the charity’s activities and are confident that the charity can continue as a going concern for a period of at least 12 months from the date of approval of these financial statements. The trustees have a reasonable expectation that the charity has adequate resources to continue in operation for the foreseeable future.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

1.4 Incoming resources

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Dividends arising on equity investments are accounted for in the year they are due and receivable.

Interest receivable on fixed interest securities and cash deposits is accrued.

1.5 Resources expended

Liabilities are recognised as expenditure once there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

The costs of generating funds consist of investment management fees.

Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice.

All expenditure is accounted for on an accruals basis. All expenses, including support costs and governance costs, are allocated to the one charitable activity in the statement of financial activities.

• 11 -

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

1 Accounting policies

(Continued)

Irrecoverable VAT is charged against the expenditure heading for which it was incurred.

1.6 Fixed asset investments

Fixed asset investments are initially measured at transaction price excluding transaction costs, and are subsequently measured at fair value at each reporting date. Changes in fair value are recognised in net income/(expenditure) for the year . Transaction costs are expensed as incurred.

1.7 Financial instruments

The c harity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value, with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

1.8 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.9 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity’s accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any critical accounting estimates or judgements applied in the preparation of the financial statements.

3 Donations and legacies

	Unrestricted	Unrestricted
	funds	funds
	general	general
	2021	2020
	£	£
Donations	133,560	68,261

• 12 -

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

4 Investments

	Unrestricted	Unrestricted	Total	Unrestricted	Unrestricted	Total
	funds	funds		funds	funds
	general	d esignated		general	d esignated
	2021	2021	2021	2020	2020	2020
	£	£	£	£	£	£
Investment income	29	4,334	4,363	301	5,297	5,598

5 Raising funds

Investment management fees 6 Charitable activities	2021 £ 1,436 1,436	2020 £ 1,542
		1,542

Forum expenses Management f ees Grant funding of activities (see note 7) Share of support costs (see note 8) Share of governance costs (see note 8) Analysis by fund Unrestricted funds - general 7 Grants payable Grants to individuals	2021 £ 17,217 650 17,867 1,050 27,932 6,480 53,329 53,329 2021 £ 1,050 1,050	2020 £ 44,730 875
		45,605 6,000 26,677 7,614
		85,896
		85,896
		2020 £ 6,000
		6,000

• 13 -

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

8 Support costs Support costs Governance costs £ £ Staff costs 27,932 - Accountancy - 6,480 27,932 6,480 Analysed between Charitable activities 27,932 6,480	2021 Support costs Governance costs £ £ £ 27,932 26,677 - 6,480 - 7,614 34,412 26,677 7,614 34,412 26,677 7,614	2020 £ 26,677 7,614
		34,291
		34,291

Governance costs includes payments to the independent examiner of £ 2, 64 0 (2020: £ 2,520 ) for independent examination fees and £ 3,840 (20 20 : £5,094) for accountancy services.

9 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year whereas 10 of the trustees were reimbursed £ 3,313 for travel expenses in 2020.

10 Employees

Number of employees

The average monthly number employees during the year was.

	2021	2020
	Number	Number
Administration	1	1
Employment costs	2021	2020
	£	£
Wages and salaries	27,312	26,068
Other pension costs	620	609
	27,932	26,677

Key management personnel are the trustees and they received no remuneration during the current or prior year.

There were no employees whose annual remuneration was £60,000 or more in the current or prior year.

• 14 -

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

11 Net gains/(losses) on investments

			Unrestricted	Unrestricted	Unrestricted
			funds		funds
			d esignated		d esignated
			2021		2020
				£	£
	Revaluation of investments		38,443		(28,984)
	Gain/(loss) on sale of investments		2,723		1,389
			41,166		(27,595)
12	Fixed asset investments
		Listed	Cash in portfolio		Total
		investments
		£			£
	Cost or valuation
	At 1 April 2020	161,955	12,193		174,148
	Additions	18,657	(18,657)		-
	Valuation changes	38,443	-		38,443
	Dividend and interest received	-	4,334		4,334
	Management fee	-	(1,436)		(1,436)
	Disposals	(17,193)	19,916		2,723
	At 31 March 2021	201,862	16,350		218,212
	Carrying amount
	At 31 March 2021	201,862	16,350		218,212
	At 31 March 2020	161,955	12,193		174,148
13	Debtors
			2021		2020
	Amounts falling due within one year:		£		£
	Other debtors		283		1,430
14	Creditors: amounts falling due within one year
			2021		2020
			£		£
	Other taxation and social security		-		1,439
	Other creditors		178		-
	Accruals and deferred income		5,880		45,900
			6,058		47,339

• 15 -

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

15 Designated funds

The income funds of the charity include the following designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes:

Balance at 1 April 2019 £ Michael Morley Investment Fund 256,988 256,988	Movement in funds Incoming resources Resources expended Revaluations, gains and losses Balance at 1 April 2020 £ £ £ £ 5,297 (1,542) (27,595) 233,148 5,297 (1,542) (27,595) 233,148	Movement in funds Incoming resources Resources expended Revaluations, gains and losses Balance at 31 March 2021 £ £ £ £ 4,334 (1,436) 41,166 277,212 4,334 (1,436) 41,166 277,212	Movement in funds Incoming resources Resources expended Revaluations, gains and losses Balance at 31 March 2021 £ £ £ £ 4,334 (1,436) 41,166 277,212 4,334 (1,436) 41,166 277,212
			277,212

The designated fund is used to hold the Charity's investments and generate income.

• 16 -

UK MYELOMA FORUM

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 MARCH 2021

16 Analysis of net assets between funds Unrestricted Designated 2021 2021 £ £ Fund balances at 31 March 2021 are represented by: Investments - 218,212 Current assets/(liabilities) 137,617 59,000 137,617 277,212	Total Unrestricted Designated 2021 2020 2020 £ £ £ 218,212 - 174,148 196,617 57,357 59,000 414,829 57,357 233,148	Total 2020 £ 174,148 116,357
		290,505

17 Analysis of changes in net funds

The charity had no debt during the year.

18 Related party transactions

There were no disclosable related party transactions during the year (2020 - none) .

• 17 -